Details of the Drug

General Information of Drug (ID: DMQ0RKZ)

Drug Name

Nimodipine

Synonyms

Admon; Brainal; Calnit; Kenesil; Modus; NimoGel; NimodipinISIS; Nimodipino; Nimodipinum; Nimotop; Periplum; Remontal; Almirall Brand of Nimodipine; Alpharma Brand of Nimodipine; Andromaco Brand of Nimodipine; Bayer Brand of Nimodipine; Bayvit Brand of Nimodipine; Cantabria Brand of Nimodipine; Elan Brand of Nimodipine; Esteve Brand of Nimodipine; Hexal Brand of Nimodipine; Nimodipin Hexal; Nimodipin ISIS; Nimodipino Bayvit; Vita Brand of Nimodipine; Bay-E 9736; DRG-0139; EG-1961; N-149; NIMOTOP (TN); Nimodipin-ISIS; Nimodipino [INN-Spanish]; Nimodipinum [INN-Latin]; Nimotop (TN); Nimotop(TM); Nimotop, Nimodipine; Bay-e-9736; Nimodipine (USAN/INN); Nimodipine [USAN:BAN:INN]; Periplum, Nimotop, BRN 0459792, DRG-0139; Isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate; 1,4-Dihydro-2,6-dimethyl-4-(3′-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl-1-methylethyl Ester; 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid; 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl 1-methylethyl ester;1-methylethyl 2-(methyloxy)ethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 2-Methoxyethyl-1-methylethyl ester; 2-methoxyethyl propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-methoxyethyl 1-methylethyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-,2-methoxyethyl 1-methylethyl ester; 3,5-pyridinecarboxylic acid 2-methoxyethyl 1-methylethyl ester; 3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl), 2-methoxyethyl 1-methylethyl ester; 3-(2-methoxyethyl) 5-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 3-O-(2-methoxyethyl) 5-O-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-N,N-dimethyl-2,2-diphenyl-butanamide

Indication

Disease Entry	ICD 11	Status	REF
Cerebral vasospasm	BA85.Z	Approved	[1], [2]

Therapeutic Class

Vasodilator Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

418.4

Topological Polar Surface Area (xlogp)

3.1

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Clearance: The drug present in the plasma can be removed from the body at the rate of 15 mL/min/kg [4]
Elimination: 0.5% of drug is excreted from urine in the unchanged form [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 1.7 - 9 hours [4]
Metabolism: The drug is metabolized via the hepatic [5]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 14.33861 micromolar/kg/day [6]
Unbound Fraction: The unbound fraction of drug in plasma is 0.016% [4]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 1.1 L/kg [4]
Water Solubility: The ability of drug to dissolve in water is measured as 0.0025 mg/mL [3]

Chemical Identifiers

Formula: C21H26N2O7
IUPAC Name: 3-O-(2-methoxyethyl) 5-O-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
Canonical SMILES: CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OCCOC
InChI: InChI=1S/C21H26N2O7/c1-12(2)30-21(25)18-14(4)22-13(3)17(20(24)29-10-9-28-5)19(18)15-7-6-8-16(11-15)23(26)27/h6-8,11-12,19,22H,9-10H2,1-5H3
InChIKey: UIAGMCDKSXEBJQ-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 4497
ChEBI ID: CHEBI:7575
CAS Number: 66085-59-4
DrugBank ID: DB00393
TTD ID: D0XN1F
VARIDT ID: DR01211
INTEDE ID: DR1161
ACDINA ID: D00470

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Calcium channel unspecific (CaC)	TT5HONZ	NOUNIPROTAC	Blocker	[7]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[8]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[9]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[10]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Nimodipine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Cefuroxime	DMSIMD8	Moderate	Increased risk of nephrotoxicity by the combination of Nimodipine and Cefuroxime.	Acute bronchitis [CA42]	[44]
Ivosidenib	DM8S6T7	Moderate	Increased metabolism of Nimodipine caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[45]
Arn-509	DMT81LZ	Major	Increased metabolism of Nimodipine caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[46]
Magnesium Sulfate	DMVEK07	Moderate	Additive neuromuscular blocking effects by the combination of Nimodipine and Magnesium Sulfate.	Acute pain [MG31]	[47]
Emapalumab	DMZG5WL	Moderate	Altered metabolism of Nimodipine due to Emapalumab alters the formation of CYP450 enzymes.	Adaptive immunity immunodeficiency [4A01]	[48]
Mitotane	DMU1GX0	Major	Increased metabolism of Nimodipine caused by Mitotane mediated induction of CYP450 enzyme.	Adrenal cancer [2D11]	[46]
Framycetin	DMF8DNE	Moderate	Increased risk of nephrotoxicity by the combination of Nimodipine and Framycetin.	Alcoholic liver disease [DB94]	[44]
Cefamandole	DMNEXZF	Moderate	Increased risk of nephrotoxicity by the combination of Nimodipine and Cefamandole.	Anaerobic bacterial infection [1A00-1A09]	[44]
Siltuximab	DMGEATB	Moderate	Altered metabolism of Nimodipine due to Siltuximab alters the formation of CYP450 enzymes.	Anemia [3A00-3A9Z]	[48]
Methylphenobarbital	DMDSWAG	Moderate	Increased metabolism of Nimodipine caused by Methylphenobarbital mediated induction of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[49]
Promazine	DMZAL7W	Moderate	Additive hypotensive effects by the combination of Nimodipine and Promazine.	Appearance/behaviour symptom [MB23]	[50]
Voriconazole	DMAOL2S	Major	Decreased metabolism of Nimodipine caused by Voriconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[51]
Posaconazole	DMUL5EW	Major	Decreased metabolism of Nimodipine caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[51]
Zileuton	DMVRIC2	Minor	Decreased metabolism of Nimodipine caused by Zileuton mediated inhibition of CYP450 enzyme.	Asthma [CA23]	[52]
Cefotetan	DM07TX3	Moderate	Increased risk of nephrotoxicity by the combination of Nimodipine and Cefotetan.	Bacterial infection [1A00-1C4Z]	[44]
Kanamycin	DM2DMPO	Moderate	Increased risk of nephrotoxicity by the combination of Nimodipine and Kanamycin.	Bacterial infection [1A00-1C4Z]	[44]
Ceftazidime	DM41GRA	Moderate	Increased risk of nephrotoxicity by the combination of Nimodipine and Ceftazidime.	Bacterial infection [1A00-1C4Z]	[44]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Nimodipine caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[53]
Clarithromycin	DM4M1SG	Major	Decreased metabolism of Nimodipine caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[51]
Cefoperazone	DM53PV8	Moderate	Increased risk of nephrotoxicity by the combination of Nimodipine and Cefoperazone.	Bacterial infection [1A00-1C4Z]	[44]
Amikacin	DM5PDRB	Moderate	Increased risk of nephrotoxicity by the combination of Nimodipine and Amikacin.	Bacterial infection [1A00-1C4Z]	[44]
Cefprozil	DM7DSYP	Moderate	Increased risk of nephrotoxicity by the combination of Nimodipine and Cefprozil.	Bacterial infection [1A00-1C4Z]	[44]
Streptomycin	DME1LQN	Moderate	Increased risk of nephrotoxicity by the combination of Nimodipine and Streptomycin.	Bacterial infection [1A00-1C4Z]	[44]
Linezolid	DMGFPU2	Moderate	Additive hypotensive effects by the combination of Nimodipine and Linezolid.	Bacterial infection [1A00-1C4Z]	[54]
Cefepime	DMHVWIK	Moderate	Increased risk of nephrotoxicity by the combination of Nimodipine and Cefepime.	Bacterial infection [1A00-1C4Z]	[44]
Cefpodoxime	DMJUNY5	Moderate	Increased risk of nephrotoxicity by the combination of Nimodipine and Cefpodoxime.	Bacterial infection [1A00-1C4Z]	[44]
Cefotaxime	DMMKHBJ	Moderate	Increased risk of nephrotoxicity by the combination of Nimodipine and Cefotaxime.	Bacterial infection [1A00-1C4Z]	[44]
Cefazolin	DMPDYFR	Moderate	Increased risk of nephrotoxicity by the combination of Nimodipine and Cefazolin.	Bacterial infection [1A00-1C4Z]	[44]
Netilmicin	DMRD1QK	Moderate	Increased risk of nephrotoxicity by the combination of Nimodipine and Netilmicin.	Bacterial infection [1A00-1C4Z]	[44]
Tobramycin	DMUI0CH	Moderate	Increased risk of nephrotoxicity by the combination of Nimodipine and Tobramycin.	Bacterial infection [1A00-1C4Z]	[44]
Cefradine	DMUNSWV	Moderate	Increased risk of nephrotoxicity by the combination of Nimodipine and Cefradine.	Bacterial infection [1A00-1C4Z]	[44]
Cefixime	DMY60I8	Moderate	Increased risk of nephrotoxicity by the combination of Nimodipine and Cefixime.	Bacterial infection [1A00-1C4Z]	[44]
Cefoxitin	DMYTXVR	Moderate	Increased risk of nephrotoxicity by the combination of Nimodipine and Cefoxitin.	Bacterial infection [1A00-1C4Z]	[44]
Telithromycin	DMZ4P3A	Major	Decreased metabolism of Nimodipine caused by Telithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[51]
Cariprazine	DMJYDVK	Moderate	Additive hypotensive effects by the combination of Nimodipine and Cariprazine.	Bipolar disorder [6A60]	[50]
Erdafitinib	DMI782S	Moderate	Increased metabolism of Nimodipine caused by Erdafitinib mediated induction of CYP450 enzyme.	Bladder cancer [2C94]	[55]
Lapatinib	DM3BH1Y	Moderate	Decreased metabolism of Nimodipine caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[56]
Tucatinib	DMBESUA	Major	Decreased metabolism of Nimodipine caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[51]
Sotalol	DML60TN	Moderate	Increased risk of cardiac depression by the combination of Nimodipine and Sotalol.	Cardiac arrhythmia [BC9Z]	[57]
Secobarbital	DM14RF5	Moderate	Increased metabolism of Nimodipine caused by Secobarbital mediated induction of CYP450 enzyme.	Chronic insomnia [7A00]	[49]
Methohexital	DM7YMIT	Moderate	Increased metabolism of Nimodipine caused by Methohexital mediated induction of CYP450 enzyme.	Corneal disease [9A76-9A78]	[49]
Thiopental	DMGP8AX	Moderate	Increased metabolism of Nimodipine caused by Thiopental mediated induction of CYP450 enzyme.	Corneal disease [9A76-9A78]	[49]
Mifepristone	DMGZQEF	Moderate	Decreased metabolism of Nimodipine caused by Mifepristone mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[44]
Pasireotide	DMHM7JS	Moderate	Increased risk of bradycardia by the combination of Nimodipine and Pasireotide.	Cushing syndrome [5A70]	[58]
Lumacaftor	DMCLWDJ	Major	Increased metabolism of Nimodipine caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[46]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Nimodipine caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[59]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Nimodipine caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[60]
Aprepitant	DM053KT	Moderate	Decreased metabolism of Nimodipine caused by Aprepitant mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[61]
Fluoxetine	DM3PD2C	Moderate	Decreased metabolism of Nimodipine caused by Fluoxetine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[58]
Nefazodone	DM4ZS8M	Major	Decreased metabolism of Nimodipine caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[51]
Selegiline	DM6034S	Moderate	Additive hypotensive effects by the combination of Nimodipine and Selegiline.	Depression [6A70-6A7Z]	[54]
Isocarboxazid	DMAF1NB	Moderate	Additive hypotensive effects by the combination of Nimodipine and Isocarboxazid.	Depression [6A70-6A7Z]	[54]
OPC-34712	DMHG57U	Moderate	Additive hypotensive effects by the combination of Nimodipine and OPC-34712.	Depression [6A70-6A7Z]	[50]
Phenelzine	DMHIDUE	Moderate	Additive hypotensive effects by the combination of Nimodipine and Phenelzine.	Depression [6A70-6A7Z]	[54]
Primidone	DM0WX6I	Major	Increased metabolism of Nimodipine caused by Primidone mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[46]
Oxcarbazepine	DM5PU6O	Moderate	Increased metabolism of Nimodipine caused by Oxcarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[62]
Mephenytoin	DM5UGDK	Moderate	Increased metabolism of Nimodipine caused by Mephenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[63]
Cenobamate	DMGOVHA	Moderate	Increased metabolism of Nimodipine caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[64]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Nimodipine caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[65]
Fosphenytoin	DMOX3LB	Major	Increased metabolism of Nimodipine caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[46]
Ethotoin	DMXWOCP	Moderate	Increased metabolism of Nimodipine caused by Ethotoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[63]
Phenobarbital	DMXZOCG	Major	Increased metabolism of Nimodipine caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[46]
Carbamazepine	DMZOLBI	Major	Increased metabolism of Nimodipine caused by Carbamazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[46]
Nadolol	DMW6GVL	Moderate	Increased risk of cardiac depression by the combination of Nimodipine and Nadolol.	Essential hypertension [BA00]	[57]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Nimodipine caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[66]
Itraconazole	DMCR1MV	Major	Decreased metabolism of Nimodipine caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[51]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Nimodipine caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[67]
Ketoconazole	DMPZI3Q	Major	Decreased metabolism of Nimodipine caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[51]
Cimetidine	DMH61ZB	Moderate	Decreased metabolism of Nimodipine caused by Cimetidine mediated inhibition of CYP450 enzyme.	Gastro-oesophageal reflux disease [DA22]	[68]
Carteolol	DMFMDOB	Moderate	Increased risk of cardiac depression by the combination of Nimodipine and Carteolol.	Glaucoma [9C61]	[57]
Metipranolol	DMJMVKI	Moderate	Increased risk of cardiac depression by the combination of Nimodipine and Metipranolol.	Glaucoma [9C61]	[69]
Levobetaxolol	DMSREPX	Moderate	Increased risk of cardiac depression by the combination of Nimodipine and Levobetaxolol.	Glaucoma [9C61]	[69]
Levobunolol	DMTNFCQ	Moderate	Increased risk of cardiac depression by the combination of Nimodipine and Levobunolol.	Glaucoma [9C61]	[69]
Carvedilol	DMHTEAO	Moderate	Increased risk of cardiac depression by the combination of Nimodipine and Carvedilol.	Heart failure [BD10-BD1Z]	[57]
Furosemide	DMMQ8ZG	Moderate	Increased risk of nephrotoxicity by the combination of Nimodipine and Furosemide.	Heart failure [BD10-BD1Z]	[44]
Boceprevir	DMBSHMF	Major	Decreased metabolism of Nimodipine caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[51]
Simeprevir	DMLUA9D	Moderate	Decreased metabolism of Nimodipine caused by Simeprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[70]
Telaprevir	DMMRV29	Major	Decreased metabolism of Nimodipine caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[51]
Rifampin	DMA8J1G	Major	Increased metabolism of Nimodipine caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[46]
Rifapentine	DMCHV4I	Major	Increased metabolism of Nimodipine caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[71]
Procarbazine	DMIK367	Moderate	Additive hypotensive effects by the combination of Nimodipine and Procarbazine.	Hodgkin lymphoma [2B30]	[54]
Delavirdine	DM3NF5G	Major	Decreased metabolism of Nimodipine caused by Delavirdine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[51]
Fosamprenavir	DM4W9B3	Moderate	Decreased metabolism of Nimodipine caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[72]
Cobicistat	DM6L4H2	Major	Decreased metabolism of Nimodipine caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[51]
Efavirenz	DMC0GSJ	Moderate	Increased metabolism of Nimodipine caused by Efavirenz mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[73]
Saquinavir	DMG814N	Major	Decreased metabolism of Nimodipine caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[51]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Nimodipine caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[74]
Amprenavir	DMLMXE0	Moderate	Decreased metabolism of Nimodipine caused by Amprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[72]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Nimodipine caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[75]
Atazanavir	DMSYRBX	Major	Decreased metabolism of Nimodipine caused by Atazanavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[51]
Ritonavir	DMU764S	Major	Decreased metabolism of Nimodipine caused by Ritonavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[51]
Acebutolol	DM0TI4U	Moderate	Increased risk of cardiac depression by the combination of Nimodipine and Acebutolol.	Hypertension [BA00-BA04]	[57]
Bisoprolol	DM3UZ95	Moderate	Increased risk of cardiac depression by the combination of Nimodipine and Bisoprolol.	Hypertension [BA00-BA04]	[57]
Penbutolol	DM4ES8F	Moderate	Increased risk of cardiac depression by the combination of Nimodipine and Penbutolol.	Hypertension [BA00-BA04]	[57]
Nebivolol	DM7F1PA	Moderate	Increased risk of cardiac depression by the combination of Nimodipine and Nebivolol.	Hypertension [BA00-BA04]	[57]
Labetalol	DMK8U72	Moderate	Increased risk of cardiac depression by the combination of Nimodipine and Labetalol.	Hypertension [BA00-BA04]	[57]
Conivaptan	DM1V329	Major	Decreased metabolism of Nimodipine caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[51]
Givosiran	DM5PFIJ	Moderate	Increased risk of nephrotoxicity by the combination of Nimodipine and Givosiran.	Inborn porphyrin/heme metabolism error [5C58]	[44]
Lesinurad	DMUR64T	Moderate	Increased metabolism of Nimodipine caused by Lesinurad mediated induction of CYP450 enzyme.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[76]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Nimodipine caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[77]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Nimodipine caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[49]
Propiomazine	DMKY8V1	Moderate	Additive hypotensive effects by the combination of Nimodipine and Propiomazine.	Insomnia [7A00-7A0Z]	[50]
ITI-007	DMUQ1DO	Moderate	Additive hypotensive effects by the combination of Nimodipine and ITI-007.	Insomnia [7A00-7A0Z]	[50]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Nimodipine caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[48]
Idelalisib	DM602WT	Major	Decreased metabolism of Nimodipine caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[51]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Nimodipine caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[78]
Propranolol	DM79NTF	Moderate	Increased risk of cardiac depression by the combination of Nimodipine and Propranolol.	Migraine [8A80]	[57]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Nimodipine caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[79]
Thalidomide	DM70BU5	Moderate	Increased risk of ventricular arrhythmias by the combination of Nimodipine and Thalidomide.	Multiple myeloma [2A83]	[44]
Siponimod	DM2R86O	Major	Increased risk of atrioventricular block by the combination of Nimodipine and Siponimod.	Multiple sclerosis [8A40]	[44]
Fingolimod	DM5JVAN	Moderate	Increased risk of bradycardia by the combination of Nimodipine and Fingolimod.	Multiple sclerosis [8A40]	[80]
Ozanimod	DMT6AM2	Moderate	Increased risk of bradycardia by the combination of Nimodipine and Ozanimod.	Multiple sclerosis [8A40]	[81]
Rifabutin	DM1YBHK	Major	Increased metabolism of Nimodipine caused by Rifabutin mediated induction of CYP450 enzyme.	Mycobacterium infection [1B10-1B21]	[71]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Nimodipine caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[48]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Nimodipine caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[82]
Imatinib	DM7RJXL	Moderate	Decreased metabolism of Nimodipine caused by Imatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[83]
Dasatinib	DMJV2EK	Moderate	Decreased metabolism of Nimodipine caused by Dasatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[84]
Modafinil	DMYILBE	Moderate	Increased metabolism of Nimodipine caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[44]
Entrectinib	DMMPTLH	Moderate	Decreased metabolism of Nimodipine caused by Entrectinib mediated inhibition of CYP450 enzyme.	Non-small cell lung cancer [2C25]	[85]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Nimodipine caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[86]
Rasagiline	DM3WKQ4	Moderate	Additive hypotensive effects by the combination of Nimodipine and Rasagiline.	Parkinsonism [8A00]	[54]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Nimodipine caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[87]
Lonafarnib	DMGM2Z6	Major	Decreased metabolism of Nimodipine caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[51]
Enzalutamide	DMGL19D	Major	Increased metabolism of Nimodipine caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[46]
Ustekinumab	DMHTYK3	Moderate	Altered metabolism of Nimodipine due to Ustekinumab alters the formation of CYP450 enzymes.	Psoriasis [EA90]	[48]
Levomepromazine	DMIKFEL	Moderate	Additive hypotensive effects by the combination of Nimodipine and Levomepromazine.	Psychotic disorder [6A20-6A25]	[50]
Fluphenazine	DMIT8LX	Moderate	Additive hypotensive effects by the combination of Nimodipine and Fluphenazine.	Psychotic disorder [6A20-6A25]	[50]
Triflupromazine	DMKFQJP	Moderate	Additive hypotensive effects by the combination of Nimodipine and Triflupromazine.	Psychotic disorder [6A20-6A25]	[50]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Nimodipine and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[88]
Tocilizumab	DM7J6OR	Moderate	Altered metabolism of Nimodipine due to Tocilizumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[48]
Canakinumab	DM8HLO5	Moderate	Altered metabolism of Nimodipine due to Canakinumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[48]
Rilonacept	DMGLUQS	Moderate	Altered metabolism of Nimodipine due to Rilonacept alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[48]
Golimumab	DMHZV7X	Moderate	Altered metabolism of Nimodipine due to Golimumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[48]
Sarilumab	DMOGNXY	Moderate	Altered metabolism of Nimodipine due to Sarilumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[48]
Quetiapine	DM1N62C	Moderate	Additive hypotensive effects by the combination of Nimodipine and Quetiapine.	Schizophrenia [6A20]	[50]
Mesoridazine	DM2ZGAN	Moderate	Additive hypotensive effects by the combination of Nimodipine and Mesoridazine.	Schizophrenia [6A20]	[50]
Thioridazine	DM35M8J	Moderate	Additive hypotensive effects by the combination of Nimodipine and Thioridazine.	Schizophrenia [6A20]	[50]
Aripiprazole	DM3NUMH	Moderate	Additive hypotensive effects by the combination of Nimodipine and Aripiprazole.	Schizophrenia [6A20]	[50]
Iloperidone	DM6AUFY	Moderate	Additive hypotensive effects by the combination of Nimodipine and Iloperidone.	Schizophrenia [6A20]	[50]
Paliperidone	DM7NPJS	Moderate	Additive hypotensive effects by the combination of Nimodipine and Paliperidone.	Schizophrenia [6A20]	[50]
Loxapine	DM8AI9U	Moderate	Additive hypotensive effects by the combination of Nimodipine and Loxapine.	Schizophrenia [6A20]	[50]
Haloperidol	DM96SE0	Moderate	Additive hypotensive effects by the combination of Nimodipine and Haloperidol.	Schizophrenia [6A20]	[50]
Perphenazine	DMA4MRX	Moderate	Additive hypotensive effects by the combination of Nimodipine and Perphenazine.	Schizophrenia [6A20]	[50]
Molindone	DMAH70G	Moderate	Additive hypotensive effects by the combination of Nimodipine and Molindone.	Schizophrenia [6A20]	[50]
Chlorpromazine	DMBGZI3	Moderate	Additive hypotensive effects by the combination of Nimodipine and Chlorpromazine.	Schizophrenia [6A20]	[50]
Thiothixene	DMDINC4	Moderate	Additive hypotensive effects by the combination of Nimodipine and Thiothixene.	Schizophrenia [6A20]	[50]
Risperidone	DMN6DXL	Moderate	Additive hypotensive effects by the combination of Nimodipine and Risperidone.	Schizophrenia [6A20]	[50]
Amisulpride	DMSJVAM	Moderate	Additive hypotensive effects by the combination of Nimodipine and Amisulpride.	Schizophrenia [6A20]	[50]
Asenapine	DMSQZE2	Moderate	Additive hypotensive effects by the combination of Nimodipine and Asenapine.	Schizophrenia [6A20]	[50]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Nimodipine caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[89]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Nimodipine caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[48]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Nimodipine caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[44]
Ifosfamide	DMCT3I8	Moderate	Increased risk of nephrotoxicity by the combination of Nimodipine and Ifosfamide.	Solid tumour/cancer [2A00-2F9Z]	[44]
Armodafinil	DMGB035	Moderate	Increased metabolism of Nimodipine caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[44]
LEE011	DMMX75K	Moderate	Decreased metabolism of Nimodipine caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[90]
Pitolisant	DM8RFNJ	Moderate	Increased metabolism of Nimodipine caused by Pitolisant mediated induction of CYP450 enzyme.	Somnolence [MG42]	[48]
Fostamatinib	DM6AUHV	Moderate	Decreased clearance of Nimodipine due to the transporter inhibition by Fostamatinib.	Thrombocytopenia [3B64]	[91]
Sirolimus	DMGW1ID	Moderate	Increased plasma concentrations of Nimodipine and Sirolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[88]
Plazomicin	DMKMBES	Moderate	Increased risk of nephrotoxicity by the combination of Nimodipine and Plazomicin.	Urinary tract infection [GC08]	[44]
Nalidixic acid	DMRM0JV	Moderate	Increased risk of nephrotoxicity by the combination of Nimodipine and Nalidixic acid.	Urinary tract infection [GC08]	[44]
Methdilazine	DMAUHQX	Moderate	Additive hypotensive effects by the combination of Nimodipine and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[50]
Trimeprazine	DMEMV9D	Moderate	Additive hypotensive effects by the combination of Nimodipine and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[92]
-----------


⏷ Show the Full List of 162 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
Isopropyl alcohol	E00070	3776	Antimicrobial preservative; Solvent
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Quinoline yellow WS	E00309	24671	Colorant
Sunset yellow FCF	E00255	17730	Colorant
Ammonia	E00007	222	Alkalizing agent
Butyl alcohol	E00011	263	Flavoring agent; Solvent
Ferrosoferric oxide	E00231	14789	Colorant
Glycerin	E00026	753	Antimicrobial preservative; Emollient; Flavoring agent; Humectant; Lubricant; Plasticizing agent; Solvent; Suppository base; Tonicity agent; Viscosity-controlling agent
Hexahydric alcohol	E00083	5780	Diluent; Flavoring agent; Humectant; Plasticizing agent
Medium-chain triglyceride	E00640	Not Available	Emollient; Lubricant; Surfactant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Water	E00035	962	Solvent
--------------------


⏷ Show the Full List of 15 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Nimodipine 30 mg capsule	30 mg	Oral Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2523).
2	Emerging treatments for traumatic brain injury. Expert Opin Emerg Drugs. 2009 Mar;14(1):67-84.
3	BDDCS applied to over 900 drugs
4	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	Influence of bupropion and calcium channel antagonists on the nicotine-induced memory-related response of mice in the elevated plus maze. Pharmacol Rep. 2009 Mar-Apr;61(2):236-44.
8	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
9	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
10	Enzyme kinetics and inhibition of nimodipine metabolism in human liver microsomes. Acta Pharmacol Sin. 2000 Aug;21(8):690-4.
11	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
12	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
13	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
14	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
15	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
16	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
17	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
18	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
19	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
20	Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
21	Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
22	Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
23	Drug Interactions Flockhart Table
24	Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
25	Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
26	Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
27	Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
28	Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
29	MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
30	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
31	Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
32	Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
33	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
34	Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
35	Effect of intracoronary nicardipine on cardiac enzymes after elective percutaneous coronary intervention. Clin Cardiol. 2009 Jun;32(6):315-20.
36	2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
37	RT-PCR and pharmacological analysis of L-and T-type calcium channels in rat carotid body. Adv Exp Med Biol. 2009;648:105-12.
38	Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7.
39	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
40	Prenatal toxicity studies in rats and rabbits with the calcium channel blocker diproteverine. Reprod Toxicol. 1996 Jan-Feb;10(1):43-9.
41	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
42	Electrophysiological properties of HBI-3000: a new antiarrhythmic agent with multiple-channel blocking properties in human ventricular myocytes. J Cardiovasc Pharmacol. 2011 Jan;57(1):79-85.
43	Inhibition by the combined Ca2+ and 5-HT2 receptor antagonist nexopamil (LU 49938) of intracoronary thrombus formation in a canine model of arterial stenosis and intimal damage. J Cardiovasc Pharmacol. 1993 Nov;22(5):687-94.
44	Cerner Multum, Inc. "Australian Product Information.".
45	Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
46	Bahls FH, Ozuna J, Ritchie DE "Interactions between calcium channel blockers and the anticonvulsants carbamazepine and phenytoin." Neurology 41 (1991): 740-2. [PMID: 2027492]
47	Benami M, Giladi Y, Shalev E "The combination of magnesium sulphate and nifedipine - a cause of neuromuscular blockade." Br J Obstet Gynaecol 101 (1994): 262-3. [PMID: 8193107]
48	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
49	Hamann SR, Blouin RA, Chang SL, et al "Effects of hemodynamic changes on the elimination kinetics of verapamil and nifedipine." J Pharmacol Exp Ther 231 (1984): 301-5. [PMID: 6491984]
50	Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
51	Product Information. Nimotop (nimodipine). Bayer, West Haven, CT.
52	Product Information. Zylo Filmtab (zileuton). Abbott Pharmaceutical, Abbott Park, IL.
53	Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
54	Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
55	Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
56	Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
57	Anastassiades CJ "Nifedipine and beta-blocker drugs." Br Med J 281 (1980): 1251-2. [PMID: 6107167]
58	Canadian Pharmacists Association.
59	Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
60	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
61	Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
62	Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
63	Ahmad S "Nifedipine-phenytoin interaction." J Am Coll Cardiol 3 (1984): 1582. [PMID: 6425385]
64	Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
65	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
66	Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
67	Heinig R, Adelmann HG, Ahr G "The effect of ketoconazole on the pharmacokinetics, pharmacodynamics and safety of nisoldipine." Eur J Clin Pharmacol 55 (1999): 57-60. [PMID: 10206086]
68	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
69	Henry M, Kay MM, Viccellio P "Cardiogenic shock associated with calcium-channel and beta blockers: reversal with intravenous calcium chloride." Am J Emerg Med 3 (1985): 334-6. [PMID: 2860911]
70	Product Information. Olysio (simeprevir). Janssen Pharmaceuticals, Titusville, NJ.
71	Product Information. Mycobutin (rifabutin). Pharmacia and Upjohn, Kalamazoo, MI.
72	Product Information. Agenerase (amprenavir). Glaxo Wellcome, Research Triangle Pk, NC.
73	Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
74	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
75	Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
76	Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
77	Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
78	Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
79	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
80	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
81	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
82	Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
83	Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
84	Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
85	Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
86	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
87	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
88	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
89	Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
90	DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
91	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
92	Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.